Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD

clipped from alzheimersreadingroom.blogspot.com A lot of good and encouraging news continues to come out of this week's Alzheimer's Association International Conference on Alzheimer's Disease 2008. --18-Month Data from an Extension of a Pivotal Trial of Dimebon in Alzheimer's --First U.S. Double-Blind Phase II Clinical Trial of IVIg (Immunotherapy) in Alzheimer's --Phase II Immunotherapy Trial with LY2062430 in Mild to Moderate Alzheimer's --Antidementia Drugs Contribute to Longer Life in People with Alzheimer's Read More......